Auris Medical Provides Update on Intranasal Betahistine Development Program
03 avr. 2020 17h00 HE
|
Auris Medical AG
Phase 1b trial with AM-201 proceeding as planned to data read-out in early May 2020Enrollment into Phase 2 trial with AM-125 impacted by COVID-19 pandemicCompany to report 2019 second-half and full...
Auris Medical Provides Update on Ongoing Clinical Trials with Intranasal Betahistine
05 mars 2020 08h30 HE
|
Auris Medical AG
Last subject had last treatment visit in Phase 1b trial with AM-201 in prevention of antipsychotic-induced weight gain and somnolence; data read-out expected for early May 2020Phase 2 trial with...
Auris Medical Highlights Publication of Study Results Demonstrating Betahistine’s Antiepileptogenic and Anticonvulsant Activity in Murine Model
25 févr. 2020 08h30 HE
|
Auris Medical AG
Hamilton, Bermuda, February 25, 2020 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology...
Auris Medical Announces Notice of Allowance for European Patent Application
10 janv. 2020 08h30 HE
|
Auris Medical AG
Received “Intention to Grant” notice from European Patent OfficeApplication covers invention of oral treatment for tinnitus Hamilton, Bermuda, January 10, 2020 – Auris Medical Holding Ltd. (NASDAQ:...
Auris Medical Announces Formation of New Subsidiary for Development Projects in Tinnitus and Hearing Loss
30 déc. 2019 08h30 HE
|
Auris Medical AG
Hamilton, Bermuda, Dec. 30, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical...
Auris Medical Announces Positive Interim Results from AM-201 Phase 1b Study in Antipsychotic-Induced Weight Gain
11 oct. 2019 08h30 HE
|
Auris Medical AG
Hamilton, Bermuda, Oct. 11, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical...
Auris Medical Receives FDA and EMA Guidance for Keyzilen® Late-Stage Clinical Development Program
13 sept. 2019 09h00 HE
|
Auris Medical AG
Hamilton, Bermuda, Sept. 13, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical...
Auris Medical Announces Notices of Allowance for U.S. and European Patent Applications Covering Intranasal Betahistine
11 sept. 2019 09h00 HE
|
Auris Medical AG
Hamilton, Bermuda, Sept. 11, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical...
Auris Medical Announces Appointment of New Chief Financial Officer
04 sept. 2019 07h00 HE
|
Auris Medical AG
Hamilton, Bermuda, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical...
Auris Medical Announces Formation of Scientific Advisory Board for Tinnitus Programs
26 août 2019 09h00 HE
|
Auris Medical AG
Hamilton, Bermuda, Aug. 26, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical...